title: Tobramycin inhalation powder manufactured by improved process in cystic fibrosis: the randomized EDIT trial.
abstract: BACKGROUND
  Tobramycin inhalation powder (TIP) was reported to be effective in two Phase III studies in patients with cystic fibrosis (CF) chronically infected with Pseudomonas aeruginosa (Pa). The EDIT study evaluated the efficacy and safety of TIP manufactured by an improved process in CF subjects aged 6-21 years.
  
  
  METHODS
  CF patients with a forced expiratory volume in 1 second (FEV₁) ≥25% to ≤80% predicted, positive Pa cultures and inhaled antipseudomonal therapy naïve (or at least for past 4 months) were enrolled into this double-blind, multicenter trial. Patients were randomized to receive TIP or placebo (1:1) twice daily for one treatment cycle (28.5 days on drug, 28 days off drug). The primary endpoint was relative change in FEV₁ percentage predicted from baseline to day 29. A pre-specified sensitivity analysis evaluated absolute change in FEV₁% predicted. Other endpoints included Pa sputum density and safety.
  
  
  RESULTS
  A total of 62 patients out of a target of 100 (mean age 12.9 years, baseline FEV₁ 59.2% predicted, Pa sputum density 7.4 log₁₀ colony forming units [CFU] per gram) were randomized. Mean treatment differences (TIP - placebo) were 5.9% (p=0.148) and 4.4% (p<0.05) for relative and absolute change in FEV₁% predicted respectively. TIP significantly reduced Pa sputum density by -1.2 log10 CFU (p=0.002). Treatment with TIP was well tolerated.
  
  
  CONCLUSIONS
  Relative change in FEV₁% predicted with TIP treatment was in the expected range based on the literature, but did not reach statistical significance versus placebo. Placebo control and use of treatment naïve patients led to significant recruitment challenges and an underpowered study with consequent impact on the generated data. However, significant improvements in other outcomes including absolute change in FEV₁% predicted and reduction in Pa sputum density indicate that TIP is efficacious and well tolerated in CF patients. CLINICALTRIALS.GOV IDENTIFIER: NCT00918957.
authors.affiliation: Pediatric Clinic, UMHAT Alexandrovska, Sofia, Bulgaria. ivankagaleva@yahoo.com
authors.forename: Ivanka
authors.initials: I
authors.lastname: Galeva
authors.forename: Michael W
authors.initials: MW
authors.lastname: Konstan
authors.forename: Mark
authors.initials: M
authors.lastname: Higgins
authors.forename: Gerhild
authors.initials: G
authors.lastname: Angyalosi
authors.forename: Florian
authors.initials: F
authors.lastname: Brockhaus
authors.forename: Simon
authors.initials: S
authors.lastname: Piggott
authors.forename: Karen
authors.initials: K
authors.lastname: Thomas
authors.forename: Alexander G
authors.initials: AG
authors.lastname: Chuchalin
mesh_terms: D000280:Administration, Inhalation; D000900:Anti-Bacterial Agents / Q000008:administration & dosage* / Q000493:pharmacokinetics / Q000627:therapeutic use; D002648:Child; D003550:Cystic Fibrosis / Q000188:drug therapy* / Q000503:physiopathology; D004311:Double-Blind Method; D005260:Female; D005541:Forced Expiratory Volume; D006801:Humans; D008297:Male; D010919:Placebos; D011208:Powders; D013147:Spirometry; D014031:Tobramycin / Q000008:administration & dosage* / Q000493:pharmacokinetics / Q000627:therapeutic use
chemical_list: D000900:Anti-Bacterial Agents; D010919:Placebos; D011208:Powders; D014031:Tobramycin